Evidence map›Paper›PMID 30390384›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2019

Citrullinated Aggrecan Epitopes as Targets of Autoreactive CD4+ T Cells in Patients With Rheumatoid Arthritis.

Cliff Rims, Hannes Uchtenhagen, Mariana J Kaplan, Carmelo Carmona-Rivera, Philip Carlucci, Katalin Mikecz, Adrienn Markovics, Jeffrey Carlin, Jane H Buckner, Eddie A James

Erratum issuedAbstract readEvaluation Study
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 63 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Autoimmunity: the neoantigen hypothesis.Frontiers in immunology · 2024
    Article
  12. Article
  13. Article
  14. Review
  15. Cytotoxic CD8Nature communications · 2023
    Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Cliff RimsBenaroya Research Institute at Virginia Mason, Seattle, Washington.
Hannes UchtenhagenBenaroya Research Institute at Virginia Mason, Seattle, Washington.
Mariana J KaplanNational Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland.
Carmelo Carmona-RiveraNational Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland.
Philip CarlucciNational Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland.
Katalin MikeczRush University Medical Center, Chicago, Illinois.
Adrienn MarkovicsRush University Medical Center, Chicago, Illinois.
Jeffrey CarlinVirginia Mason Medical Center, Seattle, Washington.
Jane H BucknerBenaroya Research Institute at Virginia Mason, Seattle, Washington.
Eddie A JamesBenaroya Research Institute at Virginia Mason, Seattle, Washington.
National Institute of Arthritis and Musculoskeletal and Skin Diseases · USVirginia Mason Medical Center · USRush University Medical Center · USBenaroya Research InstituteKarolinska University Hospital · SE

Funding

Systemic AutoimmunityZIAAR041199 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI KAPLAN, MARIANA · 2014 to 2025
$32.5M
TRAINING OF ARTHRITIS RESEARCH SCIENTISTST32AR007080 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jason Knight · 1986 to 2026
$6.3M
Prevention Center U01: Early Targets for Antigen-Specific Tolerance Induction in Preclinical Rheumatoid ArthritisU01AI101981 · NIAID · UNIVERSITY OF COLORADO DENVER · PI HOLERS, VERNON MICHAEL · 2012 to 2021
$6.2M
Immune Recognition of Citrullinated Cartilage PG Aggrecan in Autoimmune ArthritisR01AR064206 · NIAMS · RUSH UNIVERSITY MEDICAL CENTER · PI MIKECZ, KATALIN · 2013 to 2017
$1.6M
Intramural NIH HHS ZIA AR041199Knut and Alice Wallenberg FoundationNIAID NIH HHS U01 AI101981NIAMS NIH HHS R01 AR064206NIAMS NIH HHS T32 AR007080Office of the Assistant Secretary of Defense for Health Affairs W81XWH-15-1-0003
6 · The paper itself

Abstract

objectiveRecognition of citrullinated antigens such as vimentin, fibrinogen, and α-enolase is associated with rheumatoid arthritis (RA). Emerging data suggest that the matrix protein aggrecan is also recognized as a citrullinated antigen. This study was undertaken to directly visualize Cit-aggrecan-specific T cells and characterize them in patients with RA.

methodsCitrullinated aggrecan peptides with likely DRB1*04:01 binding motifs were predicted using a previously published scanning algorithm. Peptides with detectable binding were assessed for immunogenicity by HLA tetramer staining, followed by single cell cloning. Selectivity for citrullinated peptide was assessed by tetramer staining and proliferation assays. Ex vivo tetramer staining was then performed to assess frequencies of aggrecan-specific T cells in peripheral blood. Finally, disease association was assessed by comparing T cell frequencies in RA patients and controls and correlating aggrecan-specific T cells with levels of aggrecan-specific antibodies.

resultsWe identified 6 immunogenic peptides, 2 of which were the predominant T cell targets in peripheral blood. These 2 epitopes were citrullinated at HLA binding residues and shared homologous sequences. RA patients had significantly higher frequencies of Cit-aggrecan-specific T cells than healthy subjects. Furthermore, T cell frequencies were significantly correlated with antibodies against citrullinated aggrecan.

conclusionOur findings indicate that T cells that recognize citrullinated aggrecan are present in patients with RA and correlate with antibodies that target this same antigen. Consequently, aggrecan-specific T cells and antibodies are potentially relevant markers that could be used to monitor patients with RA or at-risk subjects.

Indexed as

AggrecansArthritis, RheumatoidAutoantibodiesAutoantigensCase-Control StudiesCD4-Positive T-LymphocytesCitrullineEpitopes, T-LymphocyteHLA-DRB1 ChainsHumansRegistriesAggrecansAutoantibodiesAutoantigensCitrullineEpitopes, T-LymphocyteHLA-DRB1 Chains

Identifiers

PMID30390384
PMCPMC6438725
OpenAlexW2899116898

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.